TY - JOUR
T1 - Safety of systemic therapy for noninfectious uveitis
AU - Ormaechea, Maria Soledad
AU - Hassan, Muhammad
AU - Onghanseng, Neil
AU - Park, Jung Hyun
AU - Mahajan, Sarakshi
AU - Al-Kirwi, Khalid Yusuf
AU - Uludag, Gunay
AU - Halim, Muhammad Sohail
AU - Schlaen, Ariel
AU - Sepah, Yasir J.
AU - Do, Diana V.
AU - Nguyen, Quan Dong
N1 - Funding Information:
QD Nguyen serves on the Scientific Advisory Board for AbbVie, Bayer, EyePoint, Genentech, Regeneron, and Santen, among others. QDN also chaired the Steering Committee for the VISUAL, SAVE and SAVE-2, and STOP-Uveitis studies and was on the Steering Committee for other studies sponsored by Genentech and Regeneron. The Byers Eye Institute at Stanford University receives research funding from Research to Prevent Blindness. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/12/2
Y1 - 2019/12/2
N2 - Introduction: The treatment strategies for noninfectious uveitis (NIU) aim to achieve disease remission, prevention of recurrences, and preserving vision, while minimizing the side effects associated with the therapies used. Areas covered: The index review aims to provide a detailed overview of the adverse events and safety parameters associated with the systemic therapies for the management of the NIU. Expert opinion: Despite being the cornerstone of management of acute cases of NIU, long-term corticosteroid use is associated with multi-system side effects, requiring the use of steroid-sparing agents. Adalimumab was recently approved by the FDA for the management of NIU based on the results of VISUAL studies. Similarly, newer drugs targeting various aspects of the inflammatory cascade are being developed. However, until we completely understand the molecular pathways of the inflammatory diseases, the therapeutic profile of these newer agents needs to be broad enough to suppress inflammatory cascade and narrow enough to spare normal cellular processes. Another strategy that has shown some potential in decreasing the systemic side effects is to provide local drug delivery. Therefore, the future of management of NIU is very bright with many novel therapeutic agents and strategies of drug delivery on the horizon.
AB - Introduction: The treatment strategies for noninfectious uveitis (NIU) aim to achieve disease remission, prevention of recurrences, and preserving vision, while minimizing the side effects associated with the therapies used. Areas covered: The index review aims to provide a detailed overview of the adverse events and safety parameters associated with the systemic therapies for the management of the NIU. Expert opinion: Despite being the cornerstone of management of acute cases of NIU, long-term corticosteroid use is associated with multi-system side effects, requiring the use of steroid-sparing agents. Adalimumab was recently approved by the FDA for the management of NIU based on the results of VISUAL studies. Similarly, newer drugs targeting various aspects of the inflammatory cascade are being developed. However, until we completely understand the molecular pathways of the inflammatory diseases, the therapeutic profile of these newer agents needs to be broad enough to suppress inflammatory cascade and narrow enough to spare normal cellular processes. Another strategy that has shown some potential in decreasing the systemic side effects is to provide local drug delivery. Therefore, the future of management of NIU is very bright with many novel therapeutic agents and strategies of drug delivery on the horizon.
KW - expert opinion
KW - immunomodulatory agents
KW - Noninfectious uveitis
KW - safety
KW - systemic therapies
UR - http://www.scopus.com/inward/record.url?scp=85076000792&partnerID=8YFLogxK
U2 - 10.1080/14740338.2019.1692810
DO - 10.1080/14740338.2019.1692810
M3 - Review article
C2 - 31801415
AN - SCOPUS:85076000792
SN - 1474-0338
VL - 18
SP - 1219
EP - 1235
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
IS - 12
ER -